Menu Search
Equities

Cellbxhealth PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
DWV:FRA

Cellbxhealth PLC

Actions
  • Price (EUR)0.012
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change-92.26%
  • Beta1.7576
Data delayed at least 15 minutes, as of Feb 16 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cellbxhealth PLC, formerly ANGLE plc, is a global precision circulating tumor cell (CTC) intelligence company specializing in innovative circulating tumor cell solutions for use in research, drug development and clinical oncology. The product portfolio comprises the Parsortix platform with associated consumables and assays. Its Parsortix platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology. Its Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis.Its Parsortix PR1 System is a semi-automated platform for epitope-independent CTC isolation, used in research and clinical trials for multiple cancer types.

  • Revenue in GBP (TTM)2.62m
  • Net income in GBP-15.78m
  • Incorporated2003
  • Employees119.00
  • Location
    Cellbxhealth PLCThe Surrey Research Park, 10 Nugent RoadGUILDFORD GU2 7AFUnited KingdomGBR
  • Phone+44 148 334 3434
  • Fax+44 148 368 5836
  • Websitehttps://cellbxhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.